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13-valent pneumococcal vaccines have substantially 
reduced meningitis and septicaemia in children. 
Comprehensive disease surveillance with continued 
development and implementation of vaccines against 
additional pneumococcal serotypes and serogroup 
B meningococcal disease will be needed to further 
improve control of these serious bacterial infections.
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Is tuberculosis elimination a reality? 
Multidrug-resistant (MDR) tuberculosis is a public 
health emergency and a challenging scenario for both 
patients and clinicians.1,2 In 2012, there were more than 
450 000 incident cases and 170 000 deaths worldwide.3
Treatment of MDR tuberculosis is complex and 
expensive (€100 000 or more for drugs for one patient), 
especially its most severe, extensively drug-resistant 
forms.1,2,4 Treatment is long (at least 2 years), the drugs 
are toxic (specifi c expertise is needed to manage adverse 
reactions), and the outcomes are poor (with low success 
and high death rates).1,2
New drugs will soon be available that will probably 
shorten and simplify treatment for MDR tuberculosis 
and increase eﬀ ectiveness, and public health strategies 
have been developed to prevent the occurrence of 
drug resistance.5–7 The traditional approach of national 
tuberculosis programmes, focused on tuberculosis 
control (ie, rapid diagnosis and early, eﬀ ective treat-
ment of newly detected infectious cases), which was 
advocated by the WHO Stop TB Strategy, will soon 
be replaced by the post-2015 strategy focused on 
the concept of tuberculosis elimination (ie, fewer 
than one new sputum smear-positive tuberculosis case 
per 1 million population).8,9  
Whereas traditional contact tracing (eg, looking 
for the contacts of individuals with tuberculosis and 
MDR tuberculosis in progressive circles10) recommends 
identifi cation and treatment of latently infected 
individuals and additional tuberculosis cases, new 
approaches recommend genotypic identifi cation of 
the causative strain, monitoring of the epidemic, and 
initiation of adequate measures to manage it.
One such approach is mycobacterial interspersed 
repetitive-unit-variable-number tandem repeat (MIRU-
VNTR) strain typing. In The Lancet Infectious Diseases, 
Laura F Anderson and colleagues11 report an assessment 
of transmission of MDR tuberculosis in the UK between 
2004 and 2007, using the 24-loci MIRU-VNTR method 
together with epidemiological data collected through 
the national surveillance system and an ad-hoc cluster 
investigation questionnaire. The scope was to identify the 
relative frequency of MDR tuberculosis cases transmitted 
nationwide. 204 patients were diagnosed with MDR 
tuberculosis in the study period of whom 189 (92·6%) had 
an MIRU-VNTR profi le. 15% of these cases were clustered. 
Furthermore, Anderson and colleagues analysed the risk 
factors associated with MDR tuberculosis transmission: 
being born in the UK (odds ratio 4·81; 95% CI 2·03–11·36, 
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p=0·0005) and having a history of illicit drug use 
(4·75; 1·19–18·96, p=0·026) signifi cantly increased the 
probability of transmission. Most cases (21 of 22) were 
transmitted in the household. The occurrence of MDR 
tuberculosis transmission in the UK is lower than in other 
European and non-European settings, probably as a 
consequence of scarce transmission occurring between 
specifi c population groups.
The study is an excellent example of nationwide 
implementation of one of the European Centre 
for Disease Prevention and Control (ECDC) recom-
mendations to eliminate tuberculosis in the European 
Union.12–14 Moreover, the identifi cation of risk 
factors allows the prioritisation of the public health 
investigations, reducing the probability of transmission 
related to health-care system delay.
The core strength of the study is the high proportion 
of MDR tuberculosis cases assessed with the novel 
diagnostic approach (ie, 24-loci MIRU-VNTR) and 
the ability to increase sensitivity compared with the 
traditional epidemiological investigations. However, 
other more sensitive techniques such as whole genome 
sequencing analysis could also have increased the ability 
to identify additional epidemiological links, which means 
that a potential underestimation of MDR tuberculosis 
transmission should be considered. Low culture 
confi rmation (about 60% in the UK) could also have 
underestimated the true prevalence of transmission.
Molecular methods have several public health 
applications, including identifi cation of outbreaks, 
population groups at highest risk of transmission, 
transmission across jurisdictions, transmission chains, 
reinfected and relapsing cases, and laboratory cross-
contamination.12 However, several technical problems 
currently hinder their integration into national 
tuberculosis pro grammes, including the absence of a gold 
standard to eﬀ ectively assess their discriminatory power.
The ECDC recommends12–14  monitoring and assess-
ment of transmission of drug-susceptible and 
drug-resistant mycobacterial strains by adoption of 
sensitive and specifi c molecular methods. Molecular 
fi ngerprinting, alongside classic epidemiological 
studies, will be helpful to discriminate real clusters of 
tuberculosis cases (ie, individuals infected by the same 
genotypes) and to (indirectly) assess the eﬃ  cacy of a 
tuberculosis control programme implemented at a 
national or regional level.  
If we are to make tuberculosis elimination a reality, this 
UK experience needs to be followed up in other European 
Union countries. The implementation of molecular 
methods with increased sensitivity allows the bypassing 
of low discriminatory power associated with traditional 
contact tracing procedures, scaling up part of the 
European Union’s tuberculosis elimination package.9,12–14  
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